METOROPROLOL TARTRATE
Manufacturer: Hikma Pharmaceuticals USA Inc.
Score: 145.0
Metoprolol Tartrate is a beta 1-selective adrenergic receptor blocking agent used to reduce cardiovascular mortality in hemodynamically stable patients with suspected or definite acute myocardial infarction. It is administered intravenously in a coronary care or similar unit, with an initial dose of three bolus injections of 5 mg each, followed by oral metoprolol maintenance therapy. The drug has several contraindications, including hypersensitivity to metoprolol or related derivatives, heart rate less than 45 beats per minute, and significant first-degree heart block. Common adverse reactions include tiredness, dizziness, shortness of breath, bradycardia, and hypotension. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.
Hypersensitivity to metoprolol or related derivatives, heart rate less than 45 beats per minute, and significant first-degree heart block are contraindications
Monitor blood pressure, heart rate, and electrocardiogram during administration
Three bolus injections of 5 mg each, administered at approximately 2-minute intervals
Not established